Skip to main content

Table 4 Cost-effectiveness of six TB screening strategies for a cohort of 1000 healthcare workers over 20 years: base-case scenario

From: Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis

Strategy Cost in 2015 $Can Incremental cost QALYs Increment in QALYs Incremental cost per QALY gaineda New active TB cases Increment in active TB cases prevented Incremental cost per additional TB case preventeda
Post-exposure screening only
 Tuberculin Skin Test $66,387 15,239.98 –– –– 3.03
 QuantiFERON®-TB-Gold $77,521 $11,134 15,239.85 –0.13 –– (Dominatedb) 2.97 0.06 $197,017
Targeted screening
 Tuberculin Skin Test $151,517 $85,130 15,237.96 –2.02 –– (Dominatedb) 2.83 0.14 $517,437c
 QuantiFERON®-TB-Gold $263,660 $197,273 15,236.90 –3.07 –– (Dominatedb) 2.86 –0.04 — (Dominatedb)
Annual screening
 Tuberculin Skin Test $404,956 $338,569 15,231.85 –8.12 –– (Dominatedb) 2.68 0.15 $1,717,539
 QuantiFERON®-TB-Gold $817,695 $751,308 15,227.92 –12.06 –– (Dominatedb) 2.80 –0.12 — (Dominatedb)
  1. TB tuberculosis, QALYs quality-adjusted life years
  2. aRelative to next most expensive, non-dominated strategy
  3. bDominated because it is more expensive and less effective than the proposed alternative; hence no incremental cost-effectiveness ratios are provided
  4. cIncremental cost of $426,678 per additional TB case prevented, relative to post-exposure TST screening only